• Ago H, Adachi T, Yoshida A. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus[J]. Structure, 1999, 7(): 1417-1426. doi: 10.1016/S0969-2126(00)80031-3

  • Arasappan A, Bennett F, Bogen S L, et al. 2010. Discovery of Narlaprevir (SCH 900518): a potent, second generation HCV NS3 serine protease inhibitor. ACS Med Chem Lett, 2-15-2010

  • Bain V G, Kaita K D, Marotta P. Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients[J]. Clin Gastroenterol Hepatol, 2008, 6(): 701-706. doi: 10.1016/j.cgh.2008.02.056

  • Bartenschlager R, Ahlborn-Laake L, Mous J. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions[J]. J Virol, 1993, 67(): 3835-3844.

  • Bartosch B, Dubuisson J, Cosset F L. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes[J]. J Exp Med, 2003, 197(): 633-642. doi: 10.1084/jem.20021756

  • Bavisotto L, Wang C, Jacobson I, et al. 2007. Antiviral, pharmacokinetic and safety data for GS-9190, a non-nucleoside HCV NS5B polymerase inhibitor, in a phase-1 trial in HCV genotype 1 infected patients. 58th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA.

  • Bernstein B, Menon R M, Klein C E, et al. 2009. Pharmacokinetics, safety and tolerability of the HCV protease inhibitor ABT-450 with ritonavir following multiple ascending doses in healthy adult volunteers. HepDART 2009, Kohala Coast, Hawaii, USA.

  • Blight K J, Kolykhalov A A, Rice C M. Efficient initiation of HCV RNA replication in cell culture[J]. Science, 2000, 290(): 1972-1974. doi: 10.1126/science.290.5498.1972

  • Borawski J, Troke P, Puyang X. Class Ⅲ phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication[J]. J Virol, 2009, 83(): 10058-10074. doi: 10.1128/JVI.02418-08

  • Borowski P, Deinert J, Schalinski S. Halogenated benzimidazoles and benzotriazoles as inhibitors of the NTPase/helicase activities of hepatitis C and related viruses[J]. Eur J Biochem, 2003, 270(): 1645-1653. doi: 10.1046/j.1432-1033.2003.03540.x

  • Borowski P, Lang M, Haag A. Tropolone and its derivatives as inhibitors of the helicase activity of hepatitis C virus nucleotide triphosphatase/helicase[J]. Antivir Chem Chemother, 2007, 18(): 103-109. doi: 10.1177/095632020701800206

  • Brainard D M, Anderson M S, Petry A S, et al. 2009. Safety and antiviral activity of NS5B polymerase inhibitor MK-3281in genotype 1 and 3 HCV-infected patients. 60th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA.

  • Bressanelli S, Tomei L, Roussel A. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus[J]. Proc Natl Acad Sci USA, 1999, 96(): 13034-13039. doi: 10.1073/pnas.96.23.13034

  • Bukh J. A critical role for the chimpanzee model in the study of hepatitis C[J]. Hepatology, 2004, 39(): 1469-1475. doi: 10.1002/(ISSN)1527-3350

  • Chatterji U, Bobardt M, Lim P, et al. 2010. Cyclophilin A-Independent Recruitment of NS5A and NS5B Into HCV Replication Complexes. J Gen Virol, In press.

  • Chatterji U, Bobardt M, Selvarajah S. The isomerase active site of cyclophilin A is critical for HCV replication[J]. J Biol Chem, 2009, 284(): 16998-17005. doi: 10.1074/jbc.M109.007625

  • Chatterji U, Bobardt M, Selvarajah S. The isomerase active site of cyclophilin A is critical for hepatitis C virus replication[J]. J Biol Chem, 2009, 284(): 16998-17005. doi: 10.1074/jbc.M109.007625

  • Chen C M, He Y, Lu L. Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model[J]. Antimicrob Agents Chemother, 2007, 51(): 4290-4296. doi: 10.1128/AAC.00723-07

  • Cho N J, Dvory-Sobol H, Lee C. Identification of a class of HCV inhibitors directed against the nonstructural protein NS4B[J]. Science Translational Medicine, 2010, 2(): 1-8.

  • Choo Q L, Kuo G, Weiner A J. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome[J]. Science, 1989, 244(): 359-362. doi: 10.1126/science.2523562

  • Ciesek S, Steinmann E, Wedemeyer H. Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A[J]. Hepatology, 2009, 50(): 1638-1645. doi: 10.1002/hep.23281

  • Clinicaltrials. gov. http://clinicaltrials.gov/.

  • Coelmont L, Kaptein S, Paeshuyse J. Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors[J]. Antimicrob Agents Chemother, 2009, 53(): 967-976. doi: 10.1128/AAC.00939-08

  • Colonno R. 2010. Discovery and characterization of PPI-461, a potent and selective HCV NS5A inhibitor with broad-spectrum coverage of all HCV genotypes. HCV Drug Discovery, San Diego, CA.

  • Cooper C, Lawitz E J, Ghali P. Evaluation of VCH-759 monotherapy in hepatitis C infection[J]. J Hepatol, 2009, 51(1): 39-46. doi: 10.1016/j.jhep.2009.03.015

  • Darke P L, Jacobs A R, Waxman L. Inhibition of hepatitis C virus NS2/3 processing by NS4A peptides.Implications for control of viral processing.[J]. J Biol Chem, 1999, 274(): 34511-34514. doi: 10.1074/jbc.274.49.34511

  • Einav S, Gerber D, Bryson P D. Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis[J]. Nat Biotechnol, 2008, 26(): 1019-1027. doi: 10.1038/nbt.1490

  • Elazar M, Liu M, McKenna S A. The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation[J]. Gastroenterology, 2009, 137(): 1827-1835. doi: 10.1053/j.gastro.2009.07.056

  • Erhardt A, Deterding K, Benhamou Y. Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment[J]. Antivir Ther, 2009, 14(): 23-32.

  • Evans M J, von H T, Tscherne D M. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry[J]. Nature, 2007, 446(): 801-805. doi: 10.1038/nature05654

  • Feldstein A, Kleiner D, Kravetz D. Severe hepatocellular injury with apoptosis induced by a hepatitis C polymerase inhibitor[J]. J Clin Gastroenterol, 2009, 43(): 374-381. doi: 10.1097/MCG.0b013e318178d91f

  • Fernandes F, Poole D S, Hoover S. Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B[J]. Hepatology, 2007, 46(): 1026-1033.

  • Firbas C, Boehm T, Buerger V. Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine[J]. Vaccine, 2010, 28(): 2397-2407. doi: 10.1016/j.vaccine.2009.12.072

  • Firbas C, Jilma B, Tauber E. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects[J]. Vaccine, 2006, 24(): 4343-4353. doi: 10.1016/j.vaccine.2006.03.009

  • Flisiak R, Feinman S V, Jablkowski M. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients[J]. Hepatology, 2009, 49(): 1460-1468. doi: 10.1002/hep.22835

  • Flisiak R, Feinman S V, Jablkowski M. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients[J]. Hepatology, 2009, 49(): 1460-1468. doi: 10.1002/hep.22835

  • Flisiak R, Horban A, Gallay P. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus[J]. Hepatology, 2008, 47(): 817-826. doi: 10.1002/hep.22131

  • Forestier N, Reesink H W, Weegink C J. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C[J]. Hepatology, 2007, 46(): 640-648. doi: 10.1002/hep.v46:3

  • Fried M, Shiffman M L, Reddy K R. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection[J]. N Engl J Med, 2002, 347(): 975-982. doi: 10.1056/NEJMoa020047

  • Gaither L A, Borawski J, Anderson L J. Multiple cyclophilins involved in different cellular pathways mediate HCV replication[J]. Virology, 2010, 397(): 43-55. doi: 10.1016/j.virol.2009.10.043

  • Gane E J, Oberts S K, Tedman C. First-in-man demonstration of potent antiviral activity with a nucleoside polymerase (R7128) and protease (R7227/ITMN-191) inhibitor combination in HCV: safety, pharmacokinetics, and virologic results from INFORM-1[J]. J Hepatol, 2009, 50(Suppl.1): S380 (Abstract 1046)-.

  • Gane E J, Roberts S K, Stedman C, et al. 2009. First-in-man demonstration of potent antiviral activity with a nucleoside polymerase (R7128) and protease (R7227/ITMN-191) inhibitor combination in HCV: Safety, pharmacokinetics, and virologic results from INFORM-1. 44th Annual Meeting of the European Association for the Study of the Liver. Copenhagen, Denmark.

  • Goto K, Watashi K, Inoue D. Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor[J]. Cancer Sci, 2009, 100(): 1943-1950. doi: 10.1111/cas.2009.100.issue-10

  • Gozdek A, Zhukov I, Polkowska A. NS3 Peptide, a novel potent hepatitis C virus NS3 helicase inhibitor: its mechanism of action and antiviral activity in the replicon system[J]. Antimicrob Agents Chemother, 2008, 52(): 393-401. doi: 10.1128/AAC.00961-07

  • Grakoui A, McCourt D W, Wychowski C. A second hepatitis C virus-encoded proteinase[J]. Proc Natl Acad Sci USA, 1993, 90(): 10583-10587. doi: 10.1073/pnas.90.22.10583

  • Griffin S, StGelais C, Owsianka A M. Genotype-dependent sensitivity of hepatitis C virus to inhibitors of the p7 ion channel[J]. Hepatology, 2008, 48(): 1779-1790. doi: 10.1002/hep.22555

  • Griffin S D, Beales L P, Clarke D S. The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine[J]. FEBS Lett, 2003, 535(): 34-38. doi: 10.1016/S0014-5793(02)03851-6

  • Habersetzer F, Baumert T F, Stoll-Keller F. GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection[J]. Curr Opin Mol Ther, 2009, 11(): 456-462.

  • Hanoulle X, Badillo A, Wieruszeski J M. Hepatitis C virus NS5A protein is a substrate for the Peptidyl-Prolyl cis/trans isomerase activity of Cyclophilins A and B[J]. J Biol Chem, 2009, 284(20): 13589-13601. doi: 10.1074/jbc.M809244200

  • Heck J A, Meng X, Frick D N. Cyclophilin B stimulates RNA synthesis by the HCV RNA dependent RNA polymerase[J]. Biochem Pharmacol, 2009, 77(): 1173-1180. doi: 10.1016/j.bcp.2008.12.019

  • Hendricks R T, Fell J B, Blake J F. Non-nucleoside inhibitors of HCV NS5B polymerase. Part 1: Synthetic and computational exploration of the binding modes of benzothiadiazine and 1, 4-benzothiazine HCV NS5b polymerase inhibitors[J]. Bioorg Med Chem Lett, 2009, 19(): 3637-3641. doi: 10.1016/j.bmcl.2009.04.119

  • Hezode C, Forestier N, Dusheiko G. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection[J]. N Engl J Med, 2009, 360(): 1839-1850. doi: 10.1056/NEJMoa0807650

  • Hinrichsen H, Benhamou Y, Wedemeyer H. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients[J]. Gastroenterology, 2004, 127(): 1347-1355. doi: 10.1053/j.gastro.2004.08.002

  • Hopkins S, Heuman D, Gavis E. Safety, plasma pharmacokinetics, and anti-viral activity of SCY-635 in adult patients with chronic hepatitis C virus infection[J]. J Hepatol, 2009, 50(Suppl.1): S36 (Abstract 89).-.

  • Hopkins S, Scorneaux B, Huang Z. SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro[J]. Antimicrob Agents Chemother, 2010, 54(): 660-672. doi: 10.1128/AAC.00660-09

  • Horsmans Y, Berg T, Desager J P. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection[J]. Hepatology, 2005, 42(): 724-731. doi: 10.1002/(ISSN)1527-3350

  • Howe A Y, Cheng H, Johann S. Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796[J]. Antimicrob Agents Chemother, 2008, 52(): 3327-3338. doi: 10.1128/AAC.00238-08

  • Hsu M, Zhang J, Flint M. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles[J]. Proc Natl Acad Sci USA, 2003, 100(): 7271-7276. doi: 10.1073/pnas.0832180100

  • Jirasko V, Montserret R, Appel N. Structural and functional characterization of nonstructural protein 2 for its role in hepatitis C virus assembly[J]. J Biol Chem, 2008, 283(): 28546-28562. doi: 10.1074/jbc.M803981200

  • Jones C T, Murray C L, Eastman D K. Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus[J]. J Virol, 2007, 81(): 8374-8383. doi: 10.1128/JVI.00690-07

  • Kaita K, Yoshida E, Kunimoto D. Ph Ⅱ proof of concept study of celgosivir in combination with peginterferon alfa-2b and ribavirin in chronic hepatitis C genotype 1 non-responder patients[J]. J Hepatol, 2007, 46(Suppl. 1): S56 (A127).-.

  • Kaul A, Stauffer S, Berger C. Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics[J]. PLoS Pathog, 2009, 5(8): e1000546-. doi: 10.1371/journal.ppat.1000546

  • Khoury G, Ewart G, Luscombe C. Antiviral efficacy of the novel compound BIT225 against HIV-1 release from human macrophages[J]. Antimicrob Agents Chemother, 2010, 54(): 835-845. doi: 10.1128/AAC.01308-09

  • Kim J L, Morgenstern K A, Lin C. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide[J]. Cell, 1996, 87(): 343-355. doi: 10.1016/S0092-8674(00)81351-3

  • Klade C S, Wedemeyer H, Berg T. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41[J]. Gastroenterology, 2008, 134(): 1385-1395. doi: 10.1053/j.gastro.2008.02.058

  • Korba B E, Montero A B, Farrar K. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication[J]. Antiviral Res, 2008, 77(): 56-63. doi: 10.1016/j.antiviral.2007.08.005

  • Kwo P, Lawitz E, McCone J. HCV SPRINT-1 final results: SVR 24 from a phase 2 study of boceprevir plus Pegintron™ (peginterferon alfa-2b)/ ribavirin in treatment-naive subjects with genotype-1 chronic hepatitis C[J]. J Hepatol, 2009, 50(Suppl.1): S4 (Abstract 4)-.

  • Lalezari J, Asmuth D, Casiro A, et al. 2009. Antiviral activity, safety and pharmacokinetics of IDX184, a liver-targeted nucleotide HCV polymerase inhibitor, in patients with chronic hepatitis C. 60th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA.

  • Lamarre D, Anderson P C, Bailey M. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus[J]. Nature, 2003, 426(): 186-189. doi: 10.1038/nature02099

  • Landro J A, Raybuck S A, Luong Y P. Mechanistic role of an NS4A peptide cofactor with the truncated NS3 protease of hepatitis C virus: elucidation of the NS4A stimulatory effect via kinetic analysis and inhibitor mapping[J]. Biochemistry, 1997, 36(): 9340-9348. doi: 10.1021/bi963054n

  • Larrey D, Benhamou Y, Lohse A W. Safety, pharmacokinetics and antiviral effect of BI 207127, a novel HCV RNA polymerase inhibitor, after 5 days oral treatment in patients with chronic hepatitis C[J]. J Hepatol, 2010, 50(): S383-S4 (Abstract 1054).

  • Lawitz E, Rouzier R, Nguyen, et al. 2009. Safety and antiviral efficacy of 14 days of the cyclophilin inhibitor NIM811 in combination with pegylated interferon α2A in relapsed genotype 1 HCV infected patients. 44th Annual Meeting of the European Association for the Study of the Liver. Boston, MA.

  • Lawitz E, Cooper C, Rodriguez-Torres M. Safety, tolerability and antiviral activity of VCH-916, a novel non-nucleoside hcv polymerase inhibitor in patients with chronic HCV genotype-1 infection[J]. J Hepatol, 2009, 50(Suppl.1): S37 (Abstract 92)-.

  • Lawitz E, Rodriguez-Torres M, DeMicco M. Antiviral activity of ANA598, a potent non-nucleoside polymerase inhibitor, in chronic hepatitis C patients[J]. J Hepatol, 2009, 50(Suppl.1): S384 (Abstract 1055)-.

  • Lemm J A, O'Boyle D, Liu M. Identification of hepatitis C virus NS5A inhibitors[J]. J Virol, 2010, 84(): 482-491. doi: 10.1128/JVI.01360-09

  • Lesburg C A, Cable M B, Ferrari E. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site[J]. Nat Struct Biol, 1999, 6(): 937-943. doi: 10.1038/13305

  • Li Q, Brass A L, Ng A. A genome-wide genetic screen for host factors required for hepatitis C virus propagation[J]. Proc Natl Acad Sci USA, 2009, 106(): 16410-16415. doi: 10.1073/pnas.0907439106

  • Lin K, Perni R B, Kwong A D. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells[J]. Antimicrob Agents Chemother, 2006, 50(): 1813-1822. doi: 10.1128/AAC.50.5.1813-1822.2006

  • Lin T I, Lenz O, Fanning G. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor[J]. Antimicrob Agents Chemother, 2009, 53(): 1377-1385. doi: 10.1128/AAC.01058-08

  • Lindenbach B D, Evans M J, Syder A J. Complete replication of hepatitis C virus in cell culture[J]. Science, 2005, 309(): 623-626. doi: 10.1126/science.1114016

  • Liu Z, Yang F, Robotham J M, et al. 2009. A Critical Role of Cyclophilin A and its Prolyl-Peptidyl Isomerase Activity in the Structure and Function of the HCV Replication Complex. J Virol, doi: JVI.02550-08

  • Liverton N J, Carroll S S, Dimuzio J. MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease[J]. Antimicrob Agents Chemother, 2010, 54(): 305-311. doi: 10.1128/AAC.00677-09

  • Llinas-Brunet M, Bailey M, Fazal G. Peptide-based inhibitors of the hepatitis C virus serine protease[J]. Bioorg Med Chem Lett, 1998, 8(): 1713-1718. doi: 10.1016/S0960-894X(98)00299-6

  • Lohmann V, Korner F, Koch J. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line[J]. Science, 1999, 285(): 110-113. doi: 10.1126/science.285.5424.110

  • Love R A, Brodsky O, Hickey M J. Crystal structure of a novel dimeric form of NS5A domain Ⅰ protein from hepatitis C virus[J]. J Virol, 2009, 83(): 4395-4403. doi: 10.1128/JVI.02352-08

  • Love R A, Parge H E, Wickersham J A. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site[J]. Cell, 1996, 87(): 331-342. doi: 10.1016/S0092-8674(00)81350-1

  • Luik P, Chew C, Aittoniemi J. The 3-dimensional structure of a hepatitis C virus p7 ion channel by electron microscopy[J]. Proc Natl Acad Sci USA, 2009, 106(): 12712-12716. doi: 10.1073/pnas.0905966106

  • Luscombe C A, Huang Z, Murray M G. A novel Hepatitis C virus p7 ion channel inhibitor, BIT225, inhibits bovine viral diarrhea virus in vitro and shows synergism with recombinant interferon-alpha-2b and nucleoside analogues[J]. Antiviral Res, 2010, (): -.

  • Ma S, Boerner J E, TiongYip C. NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon[J]. Antimicrob Agents Chemother, 2006, 50(): 2976-2982. doi: 10.1128/AAC.00310-06

  • Malcolm B A, Liu R, Lahser F. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells[J]. Antimicrob Agents Chemother, 2006, 50(): 1013-1020. doi: 10.1128/AAC.50.3.1013-1020.2006

  • Manns M, Bourliere M, Benhamou Y. Safety and antiviral activity of BI201335, a new HCV NS3 protease inhibitor, in combination therapy with peginterferon alfa 2a (P) and ribavirin (R) for 28 days in P+R treatment-experienced patients with chronic hepatitis C genotype-1 infection[J]. Hepatology, 2008, 48(Suppl.1): 1151A (Abstract 882)-.

  • Manns M, Bourliere M, Benhamou Y. Safety and antiviral activity of BI201335, a new HCV NS3 protease inhibitor, in treatment-naive patients with chronic hepatitis C genotype 1 infection given as monotherapy and in combination with peginterferon alfa-2a (P) and ribavirin (R)[J]. Hepatology, 2008, 48(Suppl.1): 1133A (Abstract 849).-.

  • Manns M, Muir A, Adda N. Telaprevir in hepatitis C genotype-1-infected patients with prior non-response, viral breakthrough or relapse to peginterferon-alfa-2a/b and ribavirin therapy: SVR results of the PROVE 3 study[J]. J Hepatol, 2009, 50(Supp.1): S379 (Abstract 1044)-.

  • Manns M P, McHutchison J G, Gordon S C. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial[J]. Lancet, 2001, 358(): 958-965. doi: 10.1016/S0140-6736(01)06102-5

  • Mathy J E, Ma S, Compton T. Com-binations of cyclophilin inhibitor NIM811 with hepatitis C Virus NS3-4A Protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance[J]. Antimicrob Agents Chemother, 2008, 52(): 3267-3275. doi: 10.1128/AAC.00498-08

  • McCown M F, Rajyaguru S, Le P S. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors[J]. Antimicrob Agents Chemother, 2008, 52(): 1604-1612. doi: 10.1128/AAC.01317-07

  • McHutchison J G, Everson G T, Gordon S C. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection[J]. N Engl J Med, 2009, 360(): 1827-1838. doi: 10.1056/NEJMoa0806104

  • Mercer D F, Schiller D E, Elliott J F. Hepatitis C virus replication in mice with chimeric human livers[J]. Nat.Med, 2001, 7(): 927-933. doi: 10.1038/90968

  • Nakagawa M, Sakamoto N, Enomoto N. Specific inhibition of hepatitis C virus replication by cyclosporin A[J]. Biochem Biophys Res Commun, 2004, 313(1): 42-47. doi: 10.1016/j.bbrc.2003.11.080

  • Nakagawa M, Sakamoto N, Tanabe Y. Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins[J]. Gastroenterology, 2005, 129(): 1031-1041. doi: 10.1053/j.gastro.2005.06.031

  • Nelson D R, Rustgi V, Balan V. Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C[J]. Clin Gastroenterol Hepatol, 2009, 7(): 212-218. doi: 10.1016/j.cgh.2008.10.035

  • Nettles R, Chien C, Chung E. BMS-790052 is a first-in-class potent hepatitis C virus (HCV) NS5A inhibitor for patients with chronic HCV infection: results from a proof-of-concept study[J]. Hepatology, 2008, 48(Suppl.1): 1025A (Abstract LB12)-.

  • Neumann A U, Lam N P, Dahari H. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy[J]. Science, 1998, 282(): 103-107. doi: 10.1126/science.282.5386.103

  • Ng T I, Mo H, Pilot-Matias T. Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology[J]. Hepatology, 2007, 45(): 1413-1421. doi: 10.1002/(ISSN)1527-3350

  • Nguyen T T, Gates A T, Gutshall L L. Resistance profile of a hepatitis C virus RNA-dependent RNA polymerase benzothiadiazine inhibitor[J]. Antimicrob Agents Chemother, 2003, 47(): 3525-3530. doi: 10.1128/AAC.47.11.3525-3530.2003

  • Paeshuyse J, Kaul A, De C E. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro[J]. Hepatology, 2006, 43(): 761-770. doi: 10.1002/(ISSN)1527-3350

  • Paeshuyse J, Kaul A, De C E. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro[J]. Hepatology, 2006, 43(): 761-770. doi: 10.1002/(ISSN)1527-3350

  • Pasquinelli C. et al. 2009. Safety, tolerability, pharmacokinetics and antiviral activity following single-and multiple-dose administration of BMS-650032, a novel HCV NS3 inhibitor, in subjects with chronic genotype 1HCV infection. 60th annual meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, USA.

  • Pavlovic D, Neville D C, Argaud O. The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives[J]. Proc Natl Acad Sci USA, 2003, 100(): 6104-6108. doi: 10.1073/pnas.1031527100

  • Perni R B, Almquist S J, Byrn R A. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease[J]. Antimicrob.Agents Chemother, 2006, 50(): 899-909. doi: 10.1128/AAC.50.3.899-909.2006

  • Pierra C, Amador A, Benzaria S. Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine[J]. J Med Chem, 2006, 49(): 6614-6620. doi: 10.1021/jm0603623

  • Pileri P, Uematsu Y, Campagnoli S. Binding of hepatitis C virus to CD81[J]. Science, 1998, 282(): 938-941. doi: 10.1126/science.282.5390.938

  • Ploss A, Evans M J, Gaysinskaya V A. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells[J]. Nature, 2009, 457(): 882-886. doi: 10.1038/nature07684

  • Pockros P J, Nelson D, Godofsky E. R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin[J]. Hepatology, 2008, 48(): 385-397. doi: 10.1002/hep.v48:2

  • Premkumar A, Wilson L, Ewart G D. Cation-selective ion channels formed by p7 of hepatitis C virus are blocked by hexamethylene amiloride[J]. FEBS Lett, 2004, 557(): 99-103. doi: 10.1016/S0014-5793(03)01453-4

  • Puyang X, Poulin D L, Mathy J E, et al. 2010. Mechanism of Resistance of HCV Replicons to Structurally Distinct Cyclophilin Inhibitors. Antimicrob. Agents Chemother, doi: AAC.01236-09.

  • Randolph J T, Flentge C A, Huang P P. Synthesis and biological characterization of B-ring amino analogues of potent benzothiadiazine hepatitis C virus polymerase inhibitors[J]. J Med Chem, 2009, 52(): 3174-3183. doi: 10.1021/jm801485z

  • Reesink H W, Fanning G C, Farha K A. Rapid HCV-RNA decline with once daily TMC435: a phase Ⅰ study in healthy volunteers and hepatitis C patients[J]. Gastroenterology, 2010, 138(): 913-921. doi: 10.1053/j.gastro.2009.10.033

  • Reesink H W, Zeuzem S, Weegink C J. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study[J]. Gastroenterology, 2006, 131(): 997-1002. doi: 10.1053/j.gastro.2006.07.013

  • Reiser M, Hinrichsen H, Benhamou Y. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C[J]. Hepatology, 2005, 41(): 832-835. doi: 10.1002/(ISSN)1527-3350

  • Roberts C D. 2008. Targeting HCV NS4b Function: A New Approach to Anti-HCV Activity. Inaugural HCV Drug Discovery meeting, San Diego, CA.

  • Roberts S K, Cooksley G, Dore G J. Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C[J]. Hepatology, 2008, 48(): 398-406. doi: 10.1002/hep.v48:2

  • Robida J M, Nelson H B, Liu Z. Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro[J]. J Virol, 2007, 81(): 5829-5840. doi: 10.1128/JVI.02524-06

  • Rodriguez-Torres M, Lalezari J, Gane E J. Potent antiviral response to the HCV nucleoside polymerase inhibitor R7128 for 28 days with peg-IFN and ribavirin: subanalysis by race/ethnicity, weight, and HCV genotype[J]. Hepatology, 2008, 48(Suppl.1): 1160A (Abstract 899)-.

  • Rodriguez-Torres M, Lawitz E, Flach S, et al. 2009. Antiviral activity, pharmacokinetics, safety, and tolerability of PSI-7851, a novel nucleotide polymerase inhibitor for HCV, following single and 3 Day multiple ascending oral doses in healthy volunteers and patients with chronic HCV infection. 60th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA.

  • Rodriguez-Torres M, Lawitz E, Conway B, et al. 2010. Safety and antiviral activity of the HCV non-nucleoside polymerase inhibitor VX-222 in treatment-na ve genotype 1 HCV-infected patients. 45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria,

  • Rossignol J F, Kabil S M, El-Gohary Y. Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4[J]. Aliment Pharmacol Ther, 2008, 28(): 574-580. doi: 10.1111/apt.2008.28.issue-5

  • Sakai A, Claire M S, Faulk K. The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences[J]. Proc Natl Acad Sci USA, 2003, 100(): 11646-11651. doi: 10.1073/pnas.1834545100

  • Sarrazin C, Rouzier R, Wagner F. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders[J]. Gastroenterology, 2007, 132(): 1270-1278. doi: 10.1053/j.gastro.2007.01.041

  • Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection[J]. Gastroenterology, 2010, 138(): 447-462. doi: 10.1053/j.gastro.2009.11.055

  • Scarselli E, Ansuini H, Cerino R. The human scavenger receptor class B type Ⅰ is a novel candidate receptor for the hepatitis C virus[J]. EMBO J, 2002, 21(): 5017-5025. doi: 10.1093/emboj/cdf529

  • Seiwert S D, Andrews S W, Jiang Y. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227)[J]. Antimicrob. Agents Chemother, 2008, 52(): 4432-4441. doi: 10.1128/AAC.00699-08

  • Shaw A N, Tedesco R, Bambal R. Substituted benzothiadizine inhibitors of Hepatitis C virus polymerase[J]. Bioorg Med Chem Lett, 2009, 19(): 4350-4353. doi: 10.1016/j.bmcl.2009.05.091

  • Sheaffer A K, Lee M S, Chaniewski S, et al. 2008. Resistance to a novel HCV replication inhibitor maps to amino acid changes within the NS4B Sequence. 15th International Symposium on Hepatitis C and Related Viruses, San Antonio, Texas.

  • Shi S T, Herlihy K J, Graham J P. Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase[J]. Antimicrob Agents Chemother, 2009, 53(): 2544-2552. doi: 10.1128/AAC.01599-08

  • Stankiewicz-Drogon A, Palchykovska L G, Kostina V G. New acridone-4-carboxylic acid derivatives as potential inhibitors of hepatitis C virus infection[J]. Bioorg Med Chem, 2008, 16(): 8846-8852. doi: 10.1016/j.bmc.2008.08.074

  • Steinkuhler C, Biasiol G, Brunetti M. Product inhibition of the hepatitis C virus NS3 protease[J]. Biochemistry, 1998, 37(): 8899-8905. doi: 10.1021/bi980313v

  • Steinmann E, Penin F, Kallis S. Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions[J]. PLoS Pathog, 2007, 3(): e103-. doi: 10.1371/journal.ppat.0030103

  • Steinmann E, Whitfield T, Kallis S. Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus[J]. Hepatology, 2007, 46(): 330-338.

  • Taliani M, Bianchi E, Narjes F. A continuous assay of hepatitis C virus protease based on resonance energy transfer depsipeptide substrates[J]. Anal Biochem, 1996, 240(): 60-67. doi: 10.1006/abio.1996.0331

  • Tellinghuisen T L, Marcotrigiano J, Rice C M. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase[J]. Nature, 2005, 435(): 374-379. doi: 10.1038/nature03580

  • Thibeault D, Maurice R, Pilote L. In vitro characterization of a purified NS2/3 protease variant of hepatitis C virus[J]. J Biol Chem, 2001, 276(): 46678-46684. doi: 10.1074/jbc.M108266200

  • Tomei L, Failla C, Santolini E. NS3 is a serine protease required for processing of hepatitis C virus polyprotein[J]. J Virol, 1993, 67(): 4017-4026.

  • Ujjinamatada R K, Baier A, Borowski P. An analogue of AICAR with dual inhibitory activity against WNV and HCV NTPase/helicase: synthesis and in vitro screening of 4-carbamoyl-5-(4, 6-diamino-2, 5-dihydro-1, 3, 5-triazin-2-yl) imidazole-1-beta-D-ribofura-noside[J]. Bioorg Med Chem Lett, 2007, 17(): 2285-2288. doi: 10.1016/j.bmcl.2007.01.074

  • Vaillancourt F H, Pilote L, Cartier M. Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication[J]. Virology, 2009, 387(): 5-10. doi: 10.1016/j.virol.2009.02.039

  • Wakita T, Pietschmann T, Kato T. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome[J]. Nat Med, 2005, 11(): 791-796. doi: 10.1038/nm1268

  • Watashi K, Hijikata M, Hosaka M. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes[J]. Hepatology, 2003, 38(): 1282-1288. doi: 10.1053/jhep.2003.50449

  • Watashi K, Ishii N, Hijikata M. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase[J]. Mol Cell, 2005, 19(): 111-122. doi: 10.1016/j.molcel.2005.05.014

  • Wedemeyer H, Schuller E, Schlaphoff V. Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C[J]. Vaccine, 2009, 27(): 5142-5151. doi: 10.1016/j.vaccine.2009.06.027

  • Welbourn S, Green R, Gamache I. Hepatitis C virus NS2/3 processing is required for NS3 stability and viral RNA replication[J]. J Biol Chem, 2005, 280(): 29604-29611. doi: 10.1074/jbc.M505019200

  • Whitby K, Taylor D, Patel D. Action of celgosivir (6 O-butanoyl castanospermine) against the pestivirus BVDV: implications for the treatment of hepatitis C[J]. Antivir Chem Chemother, 2004, 15(): 141-151. doi: 10.1177/095632020401500304

  • Xiang A X, Webber S E, Kerr B M. Discovery of ANA975: an oral prodrug of the TLR-7 agonist isatoribine[J]. Nucleosides Nucleotides Nucleic Acids, 2007, 26(): 635-640. doi: 10.1080/15257770701490472

  • Xue Q, Ding H, Liu M. Inhibition of hepatitis C virus replication and expression by small interfering RNA targeting host cellular genes[J]. Arch Virol, 2007, 152(): 955-962. doi: 10.1007/s00705-006-0905-x

  • Yang F, Robotham J M, Nelson H B. Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro[J]. J Virol, 2008, 82(): 5269-5278. doi: 10.1128/JVI.02614-07

  • Yang W, Zhao Y, Fabrycki J. Selection of replicon variants resistant to ACH-806, a novel hepatitis C virus inhibitor with no cross-resistance to NS3 protease and NS5B polymerase inhibitors[J]. Antimicrob. Agents Chemother, 2008, 52(): 2043-2052. doi: 10.1128/AAC.01548-07

  • Yi M, Villanueva R A, Thomas D L. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells[J]. Proc Natl Acad Sci USA, 2006, 103(): 2310-2315. doi: 10.1073/pnas.0510727103

  • Yoshida E, Kunimoto D, Lee S S. Results of a phase 2 dose ranging study of orally administered celgosivir as monotherapy in chronic hepatitis C genotype 1 patients[J]. Gastroenterology, 2006, 130(): A784-.

  • Zeuzem S, Yoshida E M, Benhamou Y. Albinterferon alfa-2b dosed every two or four weeks in interferon-naive patients with genotype 1 chronic hepatitis C[J]. Hepatology, 2008, 48(): 407-417.

  • Zhong J, Gastaminza P, Cheng G. Robust hepatitis C virus infection in vitro[J]. Proc Natl Acad Sci USA, 2005, 102(): 9294-9299. doi: 10.1073/pnas.0503596102